Clinical TrialApr 30, 2026, 04:38 PM
COCP CDI-988 Norovirus Data Presented at ICAR 2026; Phase 1b Ongoing
AI Summary
Cocrystal Pharma announced that its first oral protease inhibitor, CDI-988, for norovirus infection was featured in an oral presentation at the 39th International Conference on Antiviral Research (ICAR 2026). The presentation highlighted its novel mechanism of action and clinical advancement, including favorable Phase 1 data and the ongoing Phase 1b human challenge study, which has completed enrollment for its first cohort. CDI-988 has also been granted FDA Fast Track designation, underscoring the serious nature of norovirus and the lack of approved therapies for this infection, which carries a $60 billion annual economic burden.
Key Highlights
- CDI-988 mechanism of action and clinical advancement presented at ICAR 2026.
- Ongoing Phase 1b human challenge study for CDI-988 is fully enrolled for the first cohort.
- CDI-988 received FDA Fast Track designation for norovirus treatment and prophylaxis.
- Preclinical studies showed CDI-988 potent antiviral activity in GII.4-infected human enteronoid models.
- Phase 1 study in healthy adults showed CDI-988 was generally safe and well tolerated up to 1,200 mg.
- Norovirus causes an estimated 685 million cases and 200,000 deaths globally each year.
- Norovirus has an approximate $60 billion worldwide annual economic impact.
Price Impact
More from COCP